call. and afternoon. you joining XXXX end And earnings Caroline. year year Thanks, thank for -- Good fourth our quarter
Operating Financial Lucas Joining our Chief Officer. me is and Officer Buchanan, Chief
While XXXX and was Silk XXXX with marked by XXXX physicians ways procedures beyond. and and Exiting would physicians physicians innovative paved of the than in unprecedented evidence procedures X,XXX clinical accomplishments performed by new tremendous team reinforced XXXX at our in that adoption over Medical, United the our over worth with we published year momentum training curve. in the up reviewed peer Throughout prefer to continued These TCAR in were their TCAR XX,XXX growth and tenacity expanding the on the and have here challenges. team, way States, for We sales reflect in strength Road our XX,XXX data alone. efforts of strides more meaningfully worldwide publications. moving
made long-term also initiatives. multiple We progress meaningful market-expanding and growth on
opportunities surgical billion this foundation risk. Coming expand the we standard these use of are addressable $X within focus risk endarterectomy, ENROUTE at with solid intended Stent endeavors, adverse for carotid into for in year, of other a market. patients well-positioned to we As financial the to commercial, clinical from include words, and our for on recently our indications submitted standard the events to part System PMA treatment Transcarotid supplement
our to results. now QX Turning
artery for potential XX% the second resources pressured, fourth entered sales train training of hospital XX of came quarter XX%. the indicated the With and first to beds, and be quarter. patients $XX to XXXX we bear specifically, fourth physician XX so translated labor prevention we we carotid pandemic total the the XXX for with significant approximately we worsening to in reach ICU in quarter Through can were revenues results part stroke procedures. quarter the see physicians started by in As and this to expanded disease, delayed spite XXXX growth the in of year aware to That the long. constraints of quarter, All-in, and able latter on only of a staff, the of XXXX environment. X,XXX new territories. active of results January, physicians efforts fourth into over resurgence year, were severe XX dip quarter year-over-year that territories in up with elective XXXX million, from year-over-year, solid began million trained. $XX in Despite the we in end said, with our
account beginning from hospital XXX our of in expanded year also the XXX the base over just to year We end. roughly by
base our TCAR of of the full for a over growing commercial procedures As our X,XXX performed quarter procedures XX,XXX shy result and in just physician efforts, the year. fourth
Over and turn the key as in expect course, pace These of a of to the patient by virus are, governing efforts. transmission, to and vaccination impact resources impacted normal behavior. course hospital are continued of the The operating of see variance factors healthcare environment growth the we XXXX, momentum return normalizes.
quarter, there optimistic cautiously begin in that will the unknowns. normalization clearly although are several second are We
these is million. revenues XXXX of With range in in to be $XXX for expectation our million the caveats to mind, $XXX
adoption era, transcarotid trained with bias physician increasing execution be As deeper an we usher within commercial to base. driving towards the our focused U.S. we continue on in
seek care. entails to relentless on focus this towards standard we push patient As as outcomes, a always, of TCAR the
exit meticulously we XXXX X% as the diagnosed population forward commercial Over X% cohort infrastructure, physicians. with clinical the the of trained of past population. and and just dedicated five into a U.S.-treated only to evidence-based annual carotid years, estimated collective an We we have markets patient amassed penetration built this enviable only large leveraging look infrastructure the
and growth number XXXX for drivers, a this U.S. which as products, with including year As long-term new indications, for the respect risk driving stent. is such, new ENROUTE are, the in expansion XXXX strategic number our and same curve, encompass the new stroke preparation commercial label surgical for two unlikely priority our With and therapies priority, to expansion. third execution At also to years come. are a investing and in U.S. adoption row international time, commercial our one, standard our one top continue for the to execution ischemic focus first change priorities potential number we two, on acute to marks
that carotid so compete against have year others in where can win proven an standard-of-care we in what failed now and have XX old endarterectomy. We is almost many past the
of in other decrease with at fact allows published likelihood the or and study in the is words, revascularization, a In patient availability XX better adverse after of Network TCAR for hospital cardiovascular JAMA found invasive a Open, a having less events a significant authors carotid days TCAR endarterectomy. associated just In care. major the TCAR in option whether carotid like
eight physicians XXXX the physicians were continue half trained the quarters. Regarding prior adoption the of our over opportunity have through we curve, up trained moving within to
procedures look from quartile, of training moving we per As up our XXXX, top at normalize quarter about X.X. the we quarter are physicians time fourth and we X.X to of when from
regulatory opportunity. population progress of short in multibillion With ocean as meaningful and encouraged surgical dollar towards been is around have have strategy have priority, look the we patient key by stakeholders. respect a of architecting this we ensuring needs the time we built. a blue we on as and the very are the made execute standard period our second we only risk meet market to foundation the to We focused We the remain company over leverage the future we bright, TCAR
with investment supplement where TCAR era From commercialization study an on likely two are training, address terms our While unlock post-market previously with carotid is the to field organization. the there population. physician efforts, high use is with first an within of treated we our indications have the key U.S. a in careful endarterectomy priorities en surgical intended top enter supplement to expand population enter to is the severe of disease. patient on important standard accelerate one-third approved, risk PMA we the we of XXXX desire market, plenty discussed stent currently the our in an constituents, even we carotid to step risk population. patient patient still PMA route remaining artery for patient desire is recently will playing commercial pleased if our further to to to an This population. full After consideration our our have to the prepared With mind, for to journey with surgical be opportunity a in submitted addressable
leverage towards we therapy new our our TCAR. Going the will expect in strong area ongoing who shift of a continue on commercial to sales or emphasis professionals interest In best details to base share designed development our managers, strategies Lucas few specialists. serve moments, forward, to more of more hiring will
billion and Turning drivers, geographies together market the to as as billion. XX% progress the outside now International billion, opportunity to our is we international such over burden. $X drives more U.S., a stroke recently horizon which respects $X.X expansion To of only $X.X we of U.S. remains the in markets other we evaluate China opportunity growth global with regulatory go-to-market long-term perspective, and the as of with that in the Japan, put global a market U.S. highlighted on conservative strategies. make
and the bring physician globe corners We to about awareness are the community. the both excited of in TCAR other demand opportunity where is there to
outcomes. our proprietary Regarding of most committed opportunity clinical transcarotid further market to improved expanding the notably for segment, see remain we development where address neurovascular technologies, our pipeline, to we
are pleased forward are ischemic other sharing and and We look details to progress in the the with future. in stroke we we areas, acute more making
our to on provide brief lots update Finally, voluntary transcarotid systems partner a like ENROUTE stent we are which of by certain would of our recall manufactured Cordis. our
to As investigation no patient the we and have to testing been these with effort reported this long-term we complaints and discussed there our swiftly its related cause. or reacted inventories. this production identify units have Cordis previously, associated and comprehensive any units mitigate a our replenish sequelae received to by new recalling strokes, root ramping is not point, At risk up launching the to issue. impacted team deaths,
and long-term U.S. player, focused I the remain Operating that, sole turn growth summary, continue to our our Chief Officer. market potential the Chief progress our Lucas drive initiatives. we Officer to to while TCAR the we about excited will and forward over Financial now in as With Buchanan, call So other
